Bristol Camzyos Phase 3 Efficacy, Safety in Adolescent Obstructive Hypertrophic Cardiomyopathy (oHCM)

 Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28

Results demonstrate the potential for Camzyos to be the first targeted pharmacological therapy for the treatment of oHCM in adolescents

Safety profile of Camzyos in adolescents was similar to established profile in adults, with no new safety signals and no patients experiencing left ventricular ejection fraction (LVEF) of <50%

https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Presents-Positive-Results-from-Phase-3-SCOUT-HCM-Trial-Demonstrating-Efficacy-and-Safety-of-Camzyos-mavacamten-in-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspx